y   T cell therapy for the treatment of XXXX .

@entity1 @entity137 @entity66 @entity5 @entity1149 @entity74 @entity1199 @entity4381
y   T cells are attractive effector cells for @entity5 immunotherapy as they can secrete cytokines abundantly and exert potent @entity137 against a wide range of @entity5 cells. They comprise 1-5% of peripheral blood T cells, the majority expressing the Vy9V  2 T cell receptor that recognizes phosphoantigens. Direct in vivo activation of Vy9V  2 T cells in @entity5 @entity1 as well as adoptive transfer of ex vivo expanded Vy9V  2 T cells has been investigated in several clinical trials. We previously established a large-scale in vitro expansion method for Vy9V  2 T cells using @entity4381 and @entity1199 ( @entity1199 ). We found that Vy9V  2 T cells from @entity1 with @entity5 as well as from healthy donors underwent extensive proliferation under these conditions. Such cultured Vy9V  2 T cells retained cytokine secretion capacity and mediated @entity137 against a variety of @entity5 cell lines. Recently, we conducted a phase I clinical study to evaluate safety and potential anti- @entity5 effects of re-infusing ex vivo expanded y   T cells in @entity1 with advanced or recurrent @entity1149 ( @entity1149 ) refractory to or intolerant of current conventional treatments. There were no severe adverse events related to the therapy. All @entity1 remained alive during the study period with a median survival of 589 days and median progression-free survival of 126 days. Six @entity1 had @entity66 ( @entity66 ), whereas the remaining six evaluable @entity1 experienced @entity74 ( @entity74 ) four weeks after the sixth transfer. We conclude that adoptive transfer of @entity4381 -expanded y   T cells is safe and feasible in @entity1 with @entity1149 , refractory to other treatments.
